NCT06183658: GHABS

Greater-Bay-Area Healthy Aging Brain Study (GHABS)

Recruiting now Last updated 14 May 2025

What this trial tests

trial testing Fluids biomarker and neuroimaging of AD diagnosis in Alzheimer's Disease in 1,400 participants. Currently enrolling.

Timeline

1 May 2021

Primary endpoint
30 April 2026

30 April 2026

Quick facts

Lead sponsor	Shenzhen Bay Laboratory
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,400
Start date	1 May 2021
Primary completion	30 April 2026
Estimated completion	30 April 2026
Sites	1 location across China

Drugs / interventions tested

• Fluids biomarker and neuroimaging of AD diagnosis

Conditions studied

• Alzheimer's Disease — all drugs for Alzheimer's Disease →

Sponsor

Shenzhen Bay Laboratory

Who can join

Adults 55 to 90, any sex, with Alzheimer's Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to learn about the pathophysiology characterization and evolutionary patterns of Alzheimer's disease (AD) in South China older adults. The primary purposes are as follows:

1. The prevalence and characteristics of AD in South China's aging population
2. Identify novel biomarkers and neuroimaging techniques for early detection and intervention of AD
3. Supporting and fertilizing novel approaches and techniques for early diagnosis and intervention of AD Participants will undergo cognitive assessments, blood sample collection, and genetic testing. Some will undergo CSF collection, stool sample collection, MRI scanning, Aβ PET scanning, and tau PET scanning.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Astrocyte reactivity is associated with tau tangle load and cortical thinning in Alzheimer's disease.
   Guo T, Li A, Sun P, He Z, et al · · 2024 · cited 30× · PMID 39080744 · DOI 10.1186/s13024-024-00750-8
2. Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS).
   Liu Z, Shi D, Cai Y, Li A, et al · · 2024 · cited 23× · PMID 38627753 · DOI 10.1186/s13195-024-01458-z
3. Microglial Reactivity Correlates with Presynaptic Loss Independent of β-Amyloid and Tau.
   Lan G, Chen X, Yang J, Sun P, et al · · 2024 · cited 12× · PMID 38356322 · DOI 10.1002/ana.26885
4. Educational attainment, Aβ, tau, and structural brain reserve in Alzheimer's disease.
   Cai Y, Fang L, Li A, Yang J, et al · · 2025 · cited 10× · PMID 39854134 · DOI 10.1002/alz.14400
5. White matter fractional anisotropy decreases precede hyperintensities in Alzheimer's disease.
   Sun P, He Z, Chu E, Fan X, et al · · 2025 · cited 9× · PMID 40398415 · DOI 10.1016/j.xcrm.2025.102138
6. Plasma N-terminal tau fragment is an amyloid-dependent biomarker in Alzheimer's disease.
   Lan G, Zhang L, Li A, Ran W, et al · · 2025 · cited 8× · PMID 39821479 · DOI 10.1002/alz.14550
7. Detecting Alzheimer's disease using digital virtual reality cognitive tests.
   Fang L, Fan X, Li A, Cai Y, et al · · 2025 · cited 1× · PMID 41451798 · DOI 10.1002/alz.71039
8. Plasma growth-associated protein 43 correlates with synaptic loss in Alzheimer's disease.
   Lan G, Li B, Wang M, Barve A, et al · · 2025 · cited 1× · PMID 41406948 · DOI 10.1016/j.xcrm.2025.102508